NCT03393780 - Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures | Biotech Hunter

Enrollment

1,018

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

April 17, 2020

Study Completion Date

July 17, 2020

Conditions

Controlled Ovarian Stimulation

Interventions

DRUG

Follitropin Delta

The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.

Trial Locations (10)

Unknown

Melbourne - IVF (there may be other sites in this country), East Melbourne

Landeskrankenhaus Feldkirch Kinderwunschzentrum (there may be other sites in this country), Feldkirch

UZ Brussel (there may be other sites in this country), Brussels

Clinique - OVO (there may be other sites in this country), Montreal

Viva Neo Praxisklinik Sydow (there may be other sites in this country), Berlin

Policlinico di Milano (there may be other sites in this country), Milan

Erasmus Medisch Centrum (there may be other sites in this country), Rotterdam

Invicta Fertility Clinic Gdansk (there may be other sites in this country), Gdansk

Clinica Eugin (there may be other sites in this country), Barcelona

The London Women Clinic (there may be other sites in this country), London